Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Trends in Oncology from ACCC Annual Report Reveal ‘Silver Lining’ of the Pandemic

May 26, 2021
By Audrey Sternberg
Article

The 2020 Trending Now in Cancer report highlighted a shift in oncology care resulting from the COVID-19 pandemic.

Results from the Association of Community Cancer Centers’ (ACCC) annual report, Trending Now in Cancer Care 2020, reveal the extent of the COVID-19 pandemic on cancer care and oncology professionals.

Straying from the organization’s typical structure of conducting surveys for the report, the team at ACCC conducted focus groups in 2020 to better understand the experiences of health care providers. This decision was made due to the high demands on multidisciplinary care providers over the previous year. Topics discussed included staffing and operational integrity, service line delivery and revenue optimization, telehealth and supportive technology, clinical research, and health equity.

“This report is critically important and unlike any other, in that we are able to identify the impact of the pandemic on cancer programs and their staff, and tailor our resources to incorporate the lessons learned over the past year,” Krista Nelson, MSW, LCSW, OSW-C, FAOSW, who is ACCC President and Program Manager of Quality and Research, Cancer Support Services & Compassion for the Providence Cancer Institute in Portland, Oregon, said in a press release. “Feedback from members reaffirmed ACCC’s commitment to focus on education and resources to promote equity, diversity, and inclusion within oncology, and build a culture of resilience for cancer care staff.”

As expected, findings of the survey showed that COVID-19 weighed heavily on providers in the oncology space. Factors contributing to the added stress ranged widely and included financial hardships from layoffs, exhaustion from burnout, and the emotional toll of social distancing measures. Managers and leaders reported that the added burden of caring for the needs of their staff was a “full-time occupation”.

In line with available research indicating that the pandemic led to a drop in cancer screenings, the focus groups confirmed that their experiences matched the findings of investigators. Adding to that, many reported that necessary screening measures have not resumed to pre-pandemic levels. As such, participants surmised that more advanced cancers at diagnosis are likely to be recorded in 2021 and beyond.

Reduced or suspended services and the overall reduction in patient volume adversely impacted revenue to the health care system. However, since oncologic services such as chemotherapy infusions and radiation treatments remained steady during the early months of the pandemic, cancer programs served to financially “shore up” the health care institutions whose other service lines diminished care.

A more robust telehealth structure emerged as a welcomed side effect of the pandemic, accounting for between 40% to 50% of patient volume in 2020. However, greater reliance on these methods of communication has created a “digital divide” where certain patients, especially those in rural areas where cell phone service and connectivity are lacking, do not have equal access.

Exacerbated by the presence of the virus, health disparities in general and those specific to oncology came to the forefront. Socioeconomic, racial and ethnic, age, gender and geographic divides are served to aggravate health outcomes, which in turn motivated cancer programs across the country to act. New efforts like extending office hours, assisting patients with transportation, and partnering with community organizations were implemented to assist those who had difficulty accessing needed care. In addition, ACCC reported that added flexibilities in clinical research have the potential to positively impact the conduct of clinical trials in the long term, which may result in untold benefits to providers and their patients.

Ultimately, the findings revealed “silver linings” to come from the disruptions of the pandemic, with focus group participants reporting “how their cancer programs and practices developed new operational approaches and workflows to minimize disruptions to staff and patients and ensure continuity of care.”

References

1. Trending now in cancer care. Association of Community Cancer Centers. May 2020. Accessed May 26, 2021. https://bit.ly/3hSG2XF

2. Association of Community Cancer Centers Releases Report: Trending Now in Cancer Care 2020. News release. Association of Community Cancer Centers. May 24, 2021. Accessed May 26, 2021. https://bit.ly/3hUpuyh

Recent Videos
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Related Content
Advertisement

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 18th 2025
Article

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


The development of non-narcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.

Optimizing Stepwise Pain Relief Management in the Perioperative GI Setting

Roman Fabbricatore
August 14th 2025
Article

The development of nonnarcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.


Cellular therapies are a treatment modality that hold promise in various cancer types.

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Tim Cortese
August 8th 2025
Article

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Related Content
Advertisement

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 18th 2025
Article

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


The development of non-narcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.

Optimizing Stepwise Pain Relief Management in the Perioperative GI Setting

Roman Fabbricatore
August 14th 2025
Article

The development of nonnarcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.


Cellular therapies are a treatment modality that hold promise in various cancer types.

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Tim Cortese
August 8th 2025
Article

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.